SG11201404496PA - Improving postural stability administering droxidopa - Google Patents
Improving postural stability administering droxidopaInfo
- Publication number
- SG11201404496PA SG11201404496PA SG11201404496PA SG11201404496PA SG11201404496PA SG 11201404496P A SG11201404496P A SG 11201404496PA SG 11201404496P A SG11201404496P A SG 11201404496PA SG 11201404496P A SG11201404496P A SG 11201404496PA SG 11201404496P A SG11201404496P A SG 11201404496PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- north carolina
- droxidopa
- charlotte
- applicant
- Prior art date
Links
- QXWYKJLNLSIPIN-SFYZADRCSA-N droxidopa Chemical compound OC(=O)[C@H](N)[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-SFYZADRCSA-N 0.000 title abstract 5
- 229960001104 droxidopa Drugs 0.000 title abstract 4
- 230000001144 postural effect Effects 0.000 title abstract 3
- 208000018737 Parkinson disease Diseases 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000001089 Multiple system atrophy Diseases 0.000 abstract 1
- 206010031127 Orthostatic hypotension Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001272 neurogenic effect Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000000306 recurrent effect Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261592755P | 2012-01-31 | 2012-01-31 | |
| PCT/US2013/023828 WO2013116325A1 (fr) | 2012-01-31 | 2013-01-30 | Amélioration de la stabilité posturale par administration de droxidopa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201404496PA true SG11201404496PA (en) | 2014-12-30 |
Family
ID=47714573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201404496PA SG11201404496PA (en) | 2012-01-31 | 2013-01-30 | Improving postural stability administering droxidopa |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130197090A1 (fr) |
| EP (1) | EP2809315A1 (fr) |
| JP (1) | JP2015505563A (fr) |
| KR (1) | KR20140131335A (fr) |
| CN (1) | CN104220059A (fr) |
| AU (1) | AU2013215282A1 (fr) |
| BR (1) | BR112014018851A2 (fr) |
| CA (1) | CA2863585A1 (fr) |
| CO (1) | CO7141467A2 (fr) |
| HK (1) | HK1200331A1 (fr) |
| IL (1) | IL233855A0 (fr) |
| IN (1) | IN2014DN07196A (fr) |
| SG (1) | SG11201404496PA (fr) |
| WO (1) | WO2013116325A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5880913B2 (ja) * | 2011-05-17 | 2016-03-09 | 三郎 佐古田 | パーキンソン病の体幹症状（姿勢反射異常）の治療剤 |
| CN104434868A (zh) * | 2013-09-18 | 2015-03-25 | 重庆圣华曦药业股份有限公司 | 一种稳定且利于在消化道溶出的屈昔多巴口服剂型 |
| CN115770244A (zh) | 2016-08-30 | 2023-03-10 | 施万生物制药研发Ip有限责任公司 | 用于治疗神经性起立性低血压的化合物 |
| US10902955B1 (en) | 2020-05-01 | 2021-01-26 | Georgetown University | Detecting COVID-19 using surrogates |
| WO2021247963A1 (fr) * | 2020-06-05 | 2021-12-09 | Senda Biosciences, Inc. | (s)-alpha-fluorométhyltyrosine en tant qu'inhibiteurs de décarboxylase pour une utilisation dans le traitement de l'hypotension |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3920728A (en) | 1973-08-22 | 1975-11-18 | Hoffmann La Roche | Separation and resolution of isomeric forms of 3-(3,4-dihydroxy-phenyl)-serine |
| JPS5629551A (en) | 1979-08-20 | 1981-03-24 | Sumitomo Chem Co Ltd | Preparation of optically active threo-3- 3,4- dihydroxyphenyl serine |
| US4480109A (en) | 1982-01-14 | 1984-10-30 | Sumitomo Chemical Company, Limited | Process for producing threo-3-(3,4-dihydroxyphenyl)serine |
| CA1223602A (fr) | 1983-05-25 | 1987-06-30 | Naohito Ohashi | Preparation de 3-(3,4-dihydroxyphenyl)-serine |
| JPS6098995A (ja) | 1983-11-04 | 1985-06-01 | Microbial Chem Res Found | 光学活性３−（３，４−ジヒドロキシフエニル）セリン，およびその誘導体の製造法 |
| US5288898A (en) | 1985-09-30 | 1994-02-22 | Zaidan Hojim Biseibutsu Kagaku Kenkyu Kai | N-methylphenylserine alkyl ester derivatives and uses thereof |
| DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
| YU213587A (en) | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| DE19619510A1 (de) | 1995-05-18 | 1996-11-21 | Sumitomo Chemical Co | Verfahren zur Herstellung von Threo-3-(3,4-dihydroxyphenyl)serin |
| GB9510481D0 (en) | 1995-05-24 | 1995-07-19 | Orion Yhtymae Oy | New catechol derivatives |
| GB2344819A (en) | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
| WO2005042475A2 (fr) | 2003-10-21 | 2005-05-12 | Sention, Inc. | Esters de carbamoyle inhibant la cholinesterase et liberant des agents pharmacologiquement actifs |
| DK1886678T3 (en) * | 2005-05-18 | 2017-07-10 | Sumitomo Dainippon Pharma Co Ltd | STABLE TABLET CONTAINING DROXIDOPA |
| EP1948155B1 (fr) | 2006-06-28 | 2012-03-07 | Chelsea Therapeutics Inc. | Compositions pharmaceutiques comprenant du droxidopa |
| AU2008226541B2 (en) | 2007-03-09 | 2013-05-09 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia |
-
2013
- 2013-01-30 AU AU2013215282A patent/AU2013215282A1/en not_active Abandoned
- 2013-01-30 SG SG11201404496PA patent/SG11201404496PA/en unknown
- 2013-01-30 JP JP2014555668A patent/JP2015505563A/ja active Pending
- 2013-01-30 WO PCT/US2013/023828 patent/WO2013116325A1/fr active Application Filing
- 2013-01-30 IN IN7196DEN2014 patent/IN2014DN07196A/en unknown
- 2013-01-30 CN CN201380017855.9A patent/CN104220059A/zh active Pending
- 2013-01-30 EP EP13704314.7A patent/EP2809315A1/fr not_active Withdrawn
- 2013-01-30 KR KR20147024284A patent/KR20140131335A/ko not_active Application Discontinuation
- 2013-01-30 BR BR112014018851A patent/BR112014018851A2/pt not_active IP Right Cessation
- 2013-01-30 CA CA2863585A patent/CA2863585A1/fr not_active Abandoned
- 2013-01-30 US US13/754,001 patent/US20130197090A1/en not_active Abandoned
-
2014
- 2014-07-29 IL IL233855A patent/IL233855A0/en unknown
- 2014-08-28 CO CO14189356A patent/CO7141467A2/es not_active Application Discontinuation
-
2015
- 2015-01-23 HK HK15100783.4A patent/HK1200331A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2809315A1 (fr) | 2014-12-10 |
| AU2013215282A1 (en) | 2014-08-28 |
| CO7141467A2 (es) | 2014-12-12 |
| CN104220059A (zh) | 2014-12-17 |
| KR20140131335A (ko) | 2014-11-12 |
| JP2015505563A (ja) | 2015-02-23 |
| IL233855A0 (en) | 2014-09-30 |
| BR112014018851A2 (pt) | 2017-07-04 |
| US20130197090A1 (en) | 2013-08-01 |
| IN2014DN07196A (fr) | 2015-04-24 |
| HK1200331A1 (en) | 2015-08-07 |
| CA2863585A1 (fr) | 2013-08-08 |
| WO2013116325A1 (fr) | 2013-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201407200TA (en) | Liquid formulation | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201408173WA (en) | Pyrimidinyl tyrosine kinase inhibitors | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201407241QA (en) | Syringe | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201407890VA (en) | Tetrahydropyrazolopyrimidine compounds | |
| SG11201407662WA (en) | Process for the preparation of treprostinil and derivatives thereof | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201908977SA (en) | Niraparib formulations | |
| SG11201404496PA (en) | Improving postural stability administering droxidopa | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201906958TA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds |